drugset / Trial / NCT06156280
A Clinical Study of TQH2929 in Healthy Adult Subjects
Phase 1
Completed
40 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This project is divided into a single dose escalation and a multiple dose escalation phase Ia clinical study. This is a single-center, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQH2929 injection in healthy adults.
Timeline
- Start
- 2023-11-21
- Primary completion
- 2024-08-02
- Completion
- 2025-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQH2929 | Monoclonal antibody | 1 mg/kg | — |
| Subject | TQH2929 | Monoclonal antibody | 3 mg/kg | — |
| Subject | TQH2929 | Monoclonal antibody | 10 mg/kg | — |
| Subject | TQH2929 | Monoclonal antibody | 20 mg/kg | — |
| Subject | TQH2929 | Monoclonal antibody | 30 mg/kg | — |